Clinical Trials

53 results for Prostate Cancer


Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Radiation: CyberKnife, Other: Androgen Deprivation Therapy (ADT), Radiation: Intensity Modulated radiation therapy (IMRT)
  • Study ID: NCT01985828
View Trial

A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pyruvate (13C)
  • Study ID: NCT02526368
View Trial

The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.

  • Condition: Prostate Cancer
  • Intervention: Other: Active surveillance
  • Study ID: NCT00949819
View Trial

Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost

  • Condition: Prostate Cancer
  • Study ID: NCT02016248
View Trial

Perioperative Pelvic Floor Muscle Training May Improve Recovery of Continence in Men With Localized Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy

  • Condition: Prostate Cancer, Urinary Incontinence, Pelvic Floor Physical Therapy
  • Study ID: NCT02558946
View Trial

Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial

  • Condition: Prostatic Neoplasms
  • Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
  • Study ID: NCT02102477
View Trial

Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
  • Study ID: NCT02643511
View Trial

Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study

  • Condition: Locally Advanced and Metastatic Prostate Cancer
  • Intervention: Procedure: Radical prostatectomy
  • Study ID: NCT02971358
View Trial

Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate

  • Condition: Prostate Cancer
  • Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
  • Study ID: NCT01492972
View Trial

Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa).

  • Condition: Prostatic Neoplasms, Neoplasm Metastasis
  • Study ID: NCT02138721
View Trial

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

  • Condition: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
  • Intervention: Genetic: PCR/PCR/LDR Strategy
  • Study ID: NCT00579514
View Trial

Collection of Blood From Patients With Prostate Cancer

  • Condition: Prostatic Neoplasms
  • Study ID: NCT00923221
View Trial

Canary Prostate Active Surveillance Study

  • Condition: Prostatic Neoplasms
  • Study ID: NCT00756665
View Trial

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
  • Study ID: NCT00588185
View Trial

A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch

  • Condition: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
  • Study ID: NCT00924027
View Trial

Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer

  • Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
  • Study ID: NCT00050752
View Trial

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

  • Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
  • Study ID: NCT00026884
View Trial

Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

  • Condition: Prostate Cancer
  • Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
  • Study ID: NCT00969111
View Trial

A Randomized Trial of Modifications to Radical Prostatectomy

  • Condition: Prostate Cancer
  • Intervention: Procedure: Lymph node template, Procedure: Transverse versus vertical closure, Drug: antibiotic prophylaxis
  • Study ID: NCT01407263
View Trial

Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition

  • Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
  • Study ID: NCT01441089
View Trial

Biospecimen Acquisition From Human Subjects

  • Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
  • Study ID: NCT00034216
View Trial

Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer

  • Condition: Prostate Carcinoma
  • Study ID: NCT02739659
View Trial

HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields

  • Condition: Prostate Cancer
  • Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
  • Study ID: NCT02918253
View Trial

Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)

  • Condition: Post Prostatectomy
  • Intervention: Diagnostic Test: [18F]DCFPyL PET/MRI scan, Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03160794
View Trial

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)

  • Condition: Prostate Cancer
  • Intervention: Other: Standard of Care
  • Study ID: NCT03151629
View Trial

Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer

  • Condition: Health Status Unknown, PSA Progression
  • Intervention: Procedure: Biopsy of Prostate, Other: Laboratory Biomarker Analysis, Diagnostic Test: Magnetic Resonance Imaging, Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
  • Study ID: NCT03234556
View Trial

PHASE I STUDY OF PSMA-TGFβRDN CAR MODIFIED T CELLS IN PATIENTS WITH ADVANCED CASTRATE RESISTANT PROSTATE CANCER

  • Condition: Prostate Cancer
  • Study ID: NCT03089203
View Trial

Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial

  • Condition: Prostate Cancer
  • Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
  • Study ID: NCT03482089
View Trial

Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study

  • Condition: Prostate Cancer, Bone Metastases
  • Intervention: Drug: Zoledronic Acid, Drug: Enzalutamide
  • Study ID: NCT03336983
View Trial

Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

  • Condition: Prostate Cancer, Localized Malignant Neoplasm
  • Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT01766492
View Trial

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
  • Study ID: NCT03753243
View Trial

Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies, Biological: blood test, Biological: urine test
  • Study ID: NCT03568188
View Trial

A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer

  • Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
  • Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
  • Study ID: NCT04253483
View Trial

Hypofractionated Radiosurgery for Localised Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: Hypofractionated Radiosurgery
  • Study ID: NCT03795337
View Trial

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies
  • Study ID: NCT03531099
View Trial

A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Study ID: NCT04332744
View Trial

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial

  • Condition: Oligometastatic Hormone Sensitive Prostate Cancer
  • Study ID: NCT04115007
View Trial

A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Fol

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04557059
View Trial

Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan

  • Condition: Metastatic Castration-sensitive Prostate Cancer
  • Study ID: NCT04601441
View Trial

A Phase 1, Open-Label, Single-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Castration-Sensitive Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer Being

  • Condition: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer
  • Study ID: NCT04666129
View Trial

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

  • Condition: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
  • Study ID: NCT04513717
View Trial

A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Cancer
  • Study ID: NCT05526248
View Trial

Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04984343
View Trial

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

  • Condition: Prostate Cancer
  • Study ID: NCT04422132
View Trial

Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

  • Condition: Prostate Cancer
  • Study ID: NCT05345444
View Trial

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

  • Condition: Prostate Adenocarcinoma
  • Study ID: NCT05050084
View Trial

Phase II/III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging for the Detection of PSMA Positive Tumors Using Histopathology as a Standard of Truth

  • Condition: Prostatic Neoplasms, Prostate Cancer
  • Study ID: NCT04838626
View Trial

Drug Use Investigation of Darolutamide in Addition to Standard Androgen Deprivation Therapy (ADT) and Docetaxel in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  • Condition: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • Study ID: NCT06010914
View Trial

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04396808
View Trial

A Phase I, Single Centre, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Study ID: NCT04726033
View Trial